REFERENCES
1. Dhalluin X, Scherpereel A. Treatment of malignant pleural mesothelioma: current status and future directions. Monaldi Arch Chest Dis. 2010;73:79-85.
2. Shamseddin M, Obacz J, Garnett MJ, Rintoul RC, Francies HE, Marciniak SJ. Use of preclinical models for malignant pleural mesothelioma. Thorax. 2021;76:1154-62.
3. Chen S, Zhao C, Liu R, Jiao W. A bibliometric analysis of malignant pleural mesothelioma from 2010 to 2023. J Thorac Dis. 2025;17:2014-27.
4. Amin W, Linkov F, Landsittel DP, et al. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. F1000Res. 2018;7:1184.
5. Kondola S, Manners D, Nowak AK. Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther Adv Respir Dis. 2016;10:275-88.
6. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-44.
7. Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385:1207-18.
8. Bertin B, Zugman M, Schvartsman G. The current treatment landscape of malignant pleural mesothelioma and future directions. Cancers. 2023;15:5808.
9. Felip E, Popat S, Dafni U, et al.; ETOP 13-18 BEAT-meso Collaborators. A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial. Ann Oncol. 2025;36:548-60.
10. Giri S, Lamichhane G, Pandey J, et al. Immune modulation and immunotherapy in solid tumors: mechanisms of resistance and potential therapeutic strategies. Int J Mol Sci. 2025;26:2923.
11. Abbott DM, Bortolotto C, Benvenuti S, Lancia A, Filippi AR, Stella GM. Malignant pleural mesothelioma: genetic and microenviromental heterogeneity as an unexpected reading frame and therapeutic challenge. Cancers. 2020;12:1186.
12. Chu YD, Lai MW, Yeh CT. Unlocking the potential of arginine deprivation therapy: recent breakthroughs and promising future for cancer treatment. Int J Mol Sci. 2023;24:10668.
13. National Institute for Health and Care Excellence. Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma. Available from: https://www.nice.org.uk/guidance/ta818. [Last accessed on 16 Mar 2026].
14. Arimura K, Hiroshima K, Nagashima Y, et al. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study. BMC Cancer. 2023;23:1206.
15. Chen S, Yu W, Shao S, et al. Establishment of predictive nomogram and web-based survival risk calculator for malignant pleural mesothelioma: a SEER database analysis. Front Oncol. 2022;12:1027149.
16. Field GC, Pavlyk I, Szlosarek PW. Bench-to-bedside studies of arginine deprivation in cancer. Molecules. 2023;28:2150.
17. He J, Xu S, Pan H, Li S, He J. Does size matter? - A population-based analysis of malignant pleural mesothelioma. Transl Lung Cancer Res. 2020;9:1041-52.
18. Urso L, Cavallari I, Sharova E, Ciccarese F, Pasello G, Ciminale V. Metabolic rewiring and redox alterations in malignant pleural mesothelioma. Br J Cancer. 2020;122:52-61.
19. Andujar P, Lacourt A, Brochard P, Pairon JC, Jaurand MC, Jean D. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles. J Toxicol Environ Health B Crit Rev. 2016;19:151-72.
20. Chung CTS, Da Cunha Santos G, Hwang DM, et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol. 2010;63:630-4.
21. Felley-Bosco E, MacFarlane M. Asbestos: modern insights for toxicology in the era of engineered nanomaterials. Chem Res Toxicol. 2018;31:994-1008.
22. Feun LG, Kuo MT, Savaraj N. Arginine deprivation in cancer therapy. Curr Opin Clin Nutr Metab Care. 2015;18:78-82.
23. Cvetković Z, Marković O, Marinković G, Pejić S, Vučić V. Tumor microenvironment, inflammation, and inflammatory prognostic indices in diffuse large B-cell lymphomas: a narrative review. Int J Mol Sci. 2025;26:5670.
24. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-74.
25. Barnett SE, Kenyani J, Tripari M, et al. BAP1 loss is associated with higher ASS1 expression in epithelioid mesothelioma: implications for therapeutic stratification. Mol Cancer Res. 2023;21:411-27.
26. Calabrò L, Bronte G, Grosso F, et al. Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream. Front Immunol. 2023;14:1333661.
27. Perrino M, De Vincenzo F, Cordua N, et al. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: work still in progress. Front Immunol. 2023;14:1121557.
28. Bertino P, Premeaux TA, Fujita T, et al. Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion. Oncoimmunology. 2019;8:1601482.
29. Çakan E, Lara OD, Szymanowska A, et al. Therapeutic antisense oligonucleotides in oncology: from bench to bedside. Cancers. 2024;16:2940.
30. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27-40.
31. Meirson T, Pentimalli F, Cerza F, et al. Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma. JAMA Netw Open. 2022;5:e221490.
32. López-Castro R, Fuentes-Martín Á, Medina Del Valle A, et al. Advances in immunotherapy for malignant pleural mesothelioma: from emerging strategies to translational insights. Open Respir Arch. 2024;6:100323.
33. Neilly MDJ, Pearson J, Thu AW, MacRae C, Blyth KG. Contemporary management of mesothelioma. Breathe. 2024;20:230175.
34. Scherpereel A, Mazieres J, Greillier L, et al.; French Cooperative Thoracic Intergroup. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20:239-53.
35. Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33:488-99.
36. Szlosarek PW, Creelan BC, Sarkodie T, et al.; ATOMIC-Meso Study Group. Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma: the ATOMIC-Meso randomized clinical trial. JAMA Oncol. 2024;10:475-83.
37. Nakajima EC, Vellanki PJ, Larkins E, et al. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28:446-51.
38. Kim SS, Xu S, Cui J, et al. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression. Theranostics. 2020;10:829-40.
39. Pirker C, Bilecz A, Grusch M, et al. Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup. Clin Cancer Res. 2020;26:3819-30.
40. Menis J, Pasello G, Remon J. Immunotherapy in malignant pleural mesothelioma: a review of literature data. Transl Lung Cancer Res. 2021;10:2988-3000.
41. Chu CY, Lee YC, Hsieh CH, et al. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy. Theranostics. 2021;11:3624-41.
42. Qualiotto AN, Baldavira CM, Balancin M, Ab’Saber A, Takagaki T, Capelozzi VL. Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma. Front Immunol. 2023;14:1268927.
43. Cakiroglu E, Senturk S. Genomics and functional genomics of malignant pleural mesothelioma. Int J Mol Sci. 2020;21:6342.
44. Ye LL, Peng WB, Niu YR, et al. Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis. Ann Transl Med. 2020;8:1647.
45. Harber J, Kamata T, Pritchard C, Fennell D. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy. J Immunother Cancer. 2021;9:e003032.
46. Quetel L, Meiller C, Assié JB, et al. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol Oncol. 2020;14:1207-23.
47. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J. 2006;27:1086-95.
48. Haas AR, Sterman DH. Novel intrapleural therapies for malignant diseases. Respiration. 2012;83:277-92.
49. Klampatsa A, Haas AR, Moon EK, Albelda SM. Chimeric antigen receptor (CAR) T cell therapy for malignant pleural mesothelioma (MPM). Cancers. 2017;9:115.
50. Chu GJ, van Zandwijk N, Rasko JEJ. The immune microenvironment in mesothelioma: mechanisms of resistance to immunotherapy. Front Oncol. 2019;9:1366.
51. Sayan M, Mossman BT. The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases. Part Fibre Toxicol. 2016;13:51.
52. Waldron TJ, Quatromoni JG, Karakasheva TA, Singhal S, Rustgi AK. Myeloid derived suppressor cells: targets for therapy. Oncoimmunology. 2013;2:e24117.
53. Barbone D, Van Dam L, Follo C, et al. Analysis of gene expression in 3D spheroids highlights a survival role for ASS1 in mesothelioma. PLoS ONE. 2016;11:e0150044.
54. Markowitz P, Patel M, Groisberg R, et al. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes. Cancer Treat Res Commun. 2020;25:100232.
55. Szlosarek PW, Luong P, Phillips MM, et al. Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase. J Clin Oncol. 2013;31:e111-3.
56. Sneddon S, Rive CM, Ma S, et al. Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. Oncoimmunology. 2020;9:1684713.
57. Wijdeven RH, Luk SJ, Schoufour TAW, et al. Balanced epigenetic regulation of MHC class I expression in tumor cells by the histone ubiquitin modifiers BAP1 and PCGF1. J Immunol. 2024;212:446-54.
59. Xu D, Yang H, Schmid RA, Peng RW. Therapeutic landscape of malignant pleural mesothelioma: collateral vulnerabilities and evolutionary dependencies in the spotlight. Front Oncol. 2020;10:579464.
61. Kroeger B, Manning SA, Mohan V, et al. Hippo signaling regulates the nuclear behavior and DNA binding times of YAP and TEAD to control transcription. Sci Adv. 2025;11:eadw4974.
62. Guarnaccia AD, Hagenbeek TJ, Lee W, et al. TEAD-targeting small molecules induce a cofactor switch to regulate the Hippo pathway. Proc Natl Acad Sci U S A. 2025;122:e2425984122.
63. Sato K, Faraji F, Cervantes-Villagrana RD, et al. Targeting YAP/TAZ-TEAD signaling as a therapeutic approach in head and neck squamous cell carcinoma. Cancer Lett. 2025;612:217467.
64. Agioti S, Zaravinos A. Immune cytolytic activity and strategies for therapeutic treatment. Int J Mol Sci. 2024;25:3624.
65. Luo J, Xiang X, Gong G, Jiang L. Cancer-associated fibroblast-mediated immune evasion: molecular mechanisms of stromal-immune crosstalk in the tumor microenvironment. Front Immunol. 2025;16:1617662.
66. Tanimura K, Yamada T, Omura A, et al. The impact of VEGF inhibition on clinical outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy: a retrospective cohort study. Front Oncol. 2021;11:663612.
67. Hu Q, Nonaka K, Wakiyama H, et al. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer. Cancer Med. 2021;10:3129-38.
68. Mori T, Tanaka H, Suzuki S, et al. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer. Cancer Sci. 2021;112:1746-57.
69. Yoshimoto A, Kasahara K, Saito K, Fujimura M, Nakao S. Granulocyte colony-stimulating factor-producing malignant pleural mesothelioma with the expression of other cytokines. Int J Clin Oncol. 2005;10:58-62.
70. Yang C, You J, Wang Y, et al. TLS and immune cell profiling: immunomodulatory effects of immunochemotherapy on tumor microenvironment in resectable stage III NSCLC. Front Immunol. 2024;15:1499731.
71. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187-94.
72. Marcq E, Waele J, Audenaerde JV, et al. Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. Oncotarget. 2017;8:89722-35.
73. Rovers S, Janssens A, Raskin J, et al. Recent advances of immune checkpoint inhibition and potential for (combined) TIGIT blockade as a new strategy for malignant pleural mesothelioma. Biomedicines. 2022;10:673.
74. Ruoff C, Mitchell A, Mondal P, et al. Resistance signatures manifested in early drug response across cancer types and species. Cancer Drug Resist. 2025;8:44.
75. Koyama S, Akbay EA, Li YY, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.
76. Osmanbeyoglu HU, Palmer D, Sagan A, Sementino E, Becich MJ, Testa JR. Isolated BAP1 genomic alteration in malignant pleural mesothelioma predicts distinct immunogenicity with implications for immunotherapeutic response. Cancers. 2022;14:5626.
77. Felley-Bosco E, Stahel R. Hippo/YAP pathway for targeted therapy. Transl Lung Cancer Res. 2014;3:75-83.
78. Zhang W, Wu X, Wu L, Zhang W, Zhao X. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma. Ann Transl Med. 2015;3:182.
79. Zhai K, Xie R, Ru K, Zhao M. Tertiary lymphoid structures correlate with the therapeutic efficacy and prognosis of resectable esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy plus immunotherapy. Front Immunol. 2025;16:1616247.
80. Locke M, Ghazaly E, Freitas MO, et al. Inhibition of the polyamine synthesis pathway is synthetically lethal with loss of argininosuccinate synthase 1. Cell Rep. 2016;16:1604-13.
81. Zhai K, Ma Y, Gao X, Ru K, Zhao M. Tertiary lymphoid structures in esophageal cancer: a novel target for immunotherapy. Front Immunol. 2025;16:1543322.
82. Alamri AM, Assiri AA, Khan B, Khan NU. Next-generation oncology: integrative therapeutic frontiers at the crossroads of precision genomics, immuno-engineering, and tumor microenvironment modulation. Med Oncol. 2025;42:482.
83. Su C, Chen S, He X, et al. Increased IgG4 expression within tertiary lymphoid structures of esophageal cancer and implications for prognosis. Front Immunol. 2025;16:1654655.
84. Bonsignore G, Ranzato E, Martinotti S. Unraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study. Investig New Drugs. 2025;43:634-45.
85. Li W, Zhang M, Cai S, et al. A deep learning-based model (DeepMPM) to help predict survival in patients with malignant pleural mesothelioma. Transl Cancer Res. 2023;12:2887-97.
86. Szlosarek PW, Steele JP, Nolan L, et al. Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial. JAMA Oncol. 2017;3:58-66.
87. Roznovan CN, Măruțescu LG, Gradisteanu Pircalabioru G. Immuno-oncology at the crossroads: confronting challenges in the quest for effective cancer therapies. Int J Mol Sci. 2025;26:6177.
88. Di Blasio S, Wortel IM, van Bladel DA, et al. Human CD1c+ DCs are critical cellular mediators of immune responses induced by immunogenic cell death. Oncoimmunology. 2016;5:e1192739.
89. Wang YJ, Fletcher R, Yu J, Zhang L. Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis. 2018;5:194-203.
90. Fucikova J, Kepp O, Kasikova L, et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11:1013.
91. Kozai H, Ogino H, Mitsuhashi A, et al. Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies. Thorac Cancer. 2024;15:369-78.
92. Sakakibara K, Sato T, Kufe DW, VonHoff DD, Kawabe T. CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice. Oncotarget. 2017;8:78277-88.
93. Garg AD, More S, Rufo N, et al. Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology. 2017;6:e1386829.
94. Wong DY, Ong WW, Ang WH. Induction of immunogenic cell death by chemotherapeutic platinum complexes. Angew Chem Int Ed Engl. 2015;54:6483-7.
95. Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2021;4:CD011535.
96. Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402:2295-306.
97. Aerts JG, Belderbos R, Baas P, et al.; DENIM team. Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study. Lancet Oncol. 2024;25:865-78.
98. Nowak AK, Lesterhuis WJ, Kok PS, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020;21:1213-23.
99. Forde PM, Anagnostou V, Sun Z, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021;27:1910-20.
100. Pal RS, Wahlang J, Pal Y, Chaitanya M, Saxena S. Precision oncology: transforming cancer care through personalized medicine. Med Oncol. 2025;42:246.
101. Patole VP, Shinde NV, Chandak SM, Satalkar AT. Cancer research in the 21st Century: recent advances and future perspectives. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2025;41:e20250018.
102. Robinson BWS, Redwood AJ, Creaney J. How our continuing studies of the pre-clinical inbred mouse models of mesothelioma have influenced the development of new therapies. Front Pharmacol. 2022;13:858557.
103. Douma LH, van der Noort V, Lalezari F, et al. Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study. Lancet Oncol. 2025;26:1676-84.
104. Douma LH, Lalezari F, van der Noort V, et al. Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study. Lancet Oncol. 2023;24:1219-28.
105. Popat S, Curioni-Fontecedro A, Dafni U, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 2020;31:1734-45.
106. Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212:139-48.
107. Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52:1475-85.
108. Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012;109:17561-6.
109. Chiec L, Bruno DS. Immunotherapy for treatment of pleural mesothelioma: current and emerging therapeutic strategies. Int J Mol Sci. 2024;25:10861.
110. Rovers S, Van Audenaerde J, Verloy R, et al. Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma. Oncoimmunology. 2025;14:2512104.
111. Magkouta SF, Vaitsi PC, Pappas AG, et al. CSF1/CSF1R axis blockade limits mesothelioma and enhances efficiency of anti-PDL1 immunotherapy. Cancers. 2021;13:2546.
112. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res. 2002;62:5443-50.
113. Adusumilli PS, Zauderer MG, Rivière I, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11:2748-63.
114. Davis A, Ke H, Kao S, Pavlakis N. An update on emerging therapeutic options for malignant pleural mesothelioma. Lung Cancer. 2022;13:1-12.
115. Klampatsa A, Albelda SM. Current advances in CAR T cell therapy for malignant mesothelioma. J Cell Immunol. 2020;2:192-200.
116. Haas AR, Tanyi JL, O’Hara MH, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27:1919-29.
117. Haas AR, Golden RJ, Litzky LA, et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol Ther. 2023;31:2309-25.
118. Chen Q, Lu L, Ma W. Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors. Cancers. 2022;14:5983.
119. Hiltbrunner S, Britschgi C, Schuberth P, et al. Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial. Ann Oncol. 2021;32:120-1.
120. Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol. 2012;3:283.
121. Krishnan H, Rayes J, Miyashita T, et al. Podoplanin: an emerging cancer biomarker and therapeutic target. Cancer Sci. 2018;109:1292-9.
122. Huang Z, Dewanjee S, Chakraborty P, et al. CAR T cells: engineered immune cells to treat brain cancers and beyond. Mol Cancer. 2023;22:22.
123. Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21:1089-108.
124. Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41:119.
125. Sun X, Zhao P, Lin J, Chen K, Shen J. Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system. Cancer Drug Resist. 2023;6:390-415.
126. McCarthy D, Lofgren M, Watt A, et al. Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor. Cancer Immunol Immunother. 2023;72:4195-207.
127. Sun Y, Yang H, Xu Q, et al. Anti-PD-1 nanobody-armored MSLN CAR-T therapy for malignant mesothelioma: preclinical and clinical studies. Adv Sci. ;2025:e08754.
128. Liu S, Li X, Wei W, et al. Translational selenium nanoparticles enhance NKG2D-mediated cytotoxicity of NK cells against malignant pleural mesothelioma cells through the TrxR1-pSTAT3 pathway. Nano Today. 2025;62:102720.
129. Kong X, Zhang J, Chen S, et al. Immune checkpoint inhibitors: breakthroughs in cancer treatment. Cancer Biol Med. 2024;21:451-72.
130. Kutle I, Polten R, Stalp JL, et al. Anti-mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer. Front Immunol. 2024;15:1485461.
131. Jung D, Choi E, Jeoung YH, et al. Nanobody-based CAR NK cells for possible immunotherapy of mesothelin+ tumors. Immune Netw. 2025;25:e23.
132. Castelletti L, Yeo D, van Zandwijk N, Rasko JEJ. Anti-mesothelin CAR T cell therapy for malignant mesothelioma. Biomark Res. 2021;9:11.
133. Tano ZE, Chintala NK, Li X, Adusumilli PS. Novel immunotherapy clinical trials in malignant pleural mesothelioma. Ann Transl Med. 2017;5:245.
134. Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010;181:1383-90.
135. Van den Bossche J, De Laere M, Deschepper K, et al. Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study. PLoS One. 2024;19:e0307204.
136. Terenziani R, Zoppi S, Fumarola C, Alfieri R, Bonelli M. Immunotherapeutic approaches in malignant pleural mesothelioma. Cancers. 2021;13:2793.
137. Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:676-81.
138. Obacz J, Yung H, Shamseddin M, et al. Biological basis for novel mesothelioma therapies. Br J Cancer. 2021;125:1039-55.
139. Nicolini F, Bocchini M, Bronte G, et al. Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future. Front Oncol. 2019;9:1519.
140. Dozier J, Zheng H, Adusumilli PS. Immunotherapy for malignant pleural mesothelioma: current status and future directions. Transl Lung Cancer Res. 2017;6:315-24.
141. Banerji S, Meyers DE, Harlos C, Dawe DE. The role of immunotherapy in the treatment of malignant pleural mesothelioma. Curr Oncol. 2021;28:4542-51.
142. Gray SG. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. BMC Pulm Med. 2021;21:148.
143. Zolaly MA, Mahallawi W, Khawaji ZY, Alahmadi MA. The clinical advances of oncolytic viruses in cancer immunotherapy. Cureus. 2023;15:e40742.
144. Ponce S, Cedrés S, Ricordel C, et al. ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment. J Immunother Cancer. 2023;11:e007552.
145. Kuryk L, Møller AW, Jaderberg M. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. Oncoimmunology. 2019;8:e1532763.
146. Monberg TJ, Pakola SA, Albieri B, et al. Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma. Cell Rep Med. 2025;6:102016.
147. Mondal M, Guo J, He P, Zhou D. Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother. 2020;16:2389-402.
148. Gray SG, Mutti L. Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Transl Lung Cancer Res. 2020;9 Suppl:S100-19.
149. Omolekan TO, Folahan JT, Tesfay MZ, et al. Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer’s defenses. Front Immunol. 2025;16:1618751.
150. Cheng C, Wang Q, Zhang S. Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms. Front Immunol. 2025;16:1610858.
151. Heiniö C, Clubb J, Kudling T, et al. Effective combination immunotherapy with oncolytic adenovirus and anti-PD-1 for treatment of human and murine ovarian cancers. Diseases. 2022;10:52.
152. Torricelli F, Donati B, Manicardi V, et al. CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma. J Exp Clin Cancer Res. 2025;44:256.
153. Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30:36-50.
154. Carbotti G, Dozin B, Martini S, et al. IL-27 mediates PD-L1 expression and release by human mesothelioma cells. Cancers. 2021;13:4011.
155. Ahmadzada T, Lee K, Clarke C, et al. High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. Lung Cancer. 2019;130:35-41.
156. Li X, Xiang Y, Li F, Yin C, Li B, Ke X. WNT/β-catenin signaling pathway regulating T cell-inflammation in the tumor microenvironment. Front Immunol. 2019;10:2293.
157. Zhong Z, Virshup DM. Wnt signaling and drug resistance in cancer. Mol Pharmacol. 2020;97:72-89.
158. Pai SG, Carneiro BA, Mota JM, et al. Wnt/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol. 2017;10:101.
159. Lecarpentier Y, Schussler O, Hébert JL, Vallée A. Multiple targets of the canonical WNT/β-catenin signaling in cancers. Front Oncol. 2019;9:1248.
160. Vogl M, Rosenmayr A, Bohanes T, et al. Biomarkers for malignant pleural mesothelioma - a novel view on inflammation. Cancers. 2021;13:658.
161. Caja L, Dituri F, Mancarella S, et al. TGF-β and the tissue microenvironment: relevance in fibrosis and cancer. Int J Mol Sci. 2018;19:1294.
162. Czajka-Francuz P, Prendes MJ, Mankan A, et al. Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy. Front Oncol. 2023;13:1200646.
163. Ghahremanifard P, Chanda A, Bonni S, Bose P. TGF-β mediated immune evasion in cancer-spotlight on cancer-associated fibroblasts. Cancers. 2020;12:3650.
164. Fatima S. Tumor microenvironment: a complex landscape of cancer development and drug resistance. Cureus. 2025;17:e82090.
165. Shin MH, Oh E, Kim Y, et al. Recent advances in CAR-based solid tumor immunotherapy. Cells. 2023;12:1606.
166. Lee HS, Jang HJ, Ramineni M, et al. A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma. Clin Cancer Res. 2023;29:548-59.
167. Ghafoor A, Hassan R. Somatic BAP1 loss as a predictive biomarker of overall survival in patients with malignant pleural mesothelioma treated with chemotherapy. J Thorac Oncol. 2022;17:862-4.
168. Righi L, Duregon E, Vatrano S, et al. BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study. J Thorac Oncol. 2016;11:2006-17.
169. Pinton G, Wang Z, Balzano C, et al. CDKN2A determines mesothelioma cell fate to EZH2 inhibition. Front Oncol. 2021;11:678447.
170. Gutierrez-Sainz L, Cruz P, Martinez-Recio S, et al. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression. Clin Transl Oncol. 2021;23:2030-5.
171. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375-86.
172. Sun B, Dong Y, Xu J, Wang Z. Current status and progress in immunotherapy for malignant pleural mesothelioma. Chronic Dis Transl Med. 2022;8:91-9.
173. Popat S, Baas P, Faivre-Finn C, et al.; ESMO Guidelines Committee. Electronic address: [email protected]. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:129-42.
174. Wang Q, Xu C, Wang W, et al. Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma. Thorac Cancer. 2023;14:2715-31.
175. Mansfield AS, Symanowski JT, Peikert T. Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. Lung Cancer. 2014;86:133-6.
176. Boutros CS, Risa EL, Jiang B, et al. Different diseases, different outcomes: a comparative study of peritoneal and pleural subtypes. J Surg Res. 2025;312:111-8.
177. Chintala NK, Choe JK, McGee E, et al. Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma. Front Immunol. 2023;14:1112960.
178. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003;9:2108-13.
179. Hong SH. Hippo pathway as another oncogenic mediator to promote immune evasion by PD-L1 signaling. J Thorac Dis. 2019;11 Suppl:S318-21.
180. Yang H, Hall SRR, Sun B, et al. NF2 and canonical Hippo-YAP pathway define distinct tumor subsets characterized by different immune deficiency and treatment implications in human pleural mesothelioma. Cancers. 2021;13:1561.
181. Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819-29.
182. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231-5.
183. Yoshikawa Y, Kuribayashi K, Minami T, Ohmuraya M, Kijima T. Epigenetic alterations and biomarkers for immune checkpoint inhibitors-current standards and future perspectives in malignant pleural mesothelioma treatment. Front Oncol. 2020;10:554570.
184. Peng D, Kryczek I, Nagarsheth N, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 2015;527:249-53.
185. Bhat KP, Ümit Kaniskan H, Jin J, Gozani O. Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021;20:265-86.
186. Rugo HS, Jacobs I, Sharma S, et al. The promise for histone methyltransferase inhibitors for epigenetic therapy in clinical oncology: a narrative review. Adv Ther. 2020;37:3059-82.
187. Khadeir R, Szyszko T, Szlosarek PW. Optimizing arginine deprivation for hard-to-treat cancers. Oncotarget. 2017;8:96468-9.
188. Chintala NK, Restle D, Quach H, et al. CAR T-cell therapy for pleural mesothelioma: rationale, preclinical development, and clinical trials. Lung Cancer. 2021;157:48-59.
189. Romero-Garcia S, Moreno-Altamirano MM, Prado-Garcia H, Sánchez-García FJ. Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. Front Immunol. 2016;7:52.
190. Al-Taei S, Salimu J, Spary LK, Clayton A, Lester JF, Tabi Z. Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: self-amplifying immunosuppression in cancer. Oncoimmunology. 2017;6:e1268308.
191. Cersosimo F, Barbarino M, Lonardi S, et al. Mesothelioma malignancy and the microenvironment: molecular mechanisms. Cancers. 2021;13:5664.
192. Russo A, Incorvaia L, Del Re M, et al. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM-SIAPEC-IAP-SIBioC-SIC-SIF Italian Scientific Societies. ESMO Open. 2021;6:100164.
193. Gerber B, Manzoni M, Spina V, et al. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. Haematologica. 2018;103:e245-8.
194. Desai AP, Kosari F, Disselhorst M, et al. Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy. J Immunother Cancer. 2023;11:e006035.
195. Zhang M, Liu C, Tu J, et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer. 2025;24:136.
196. Shmatko A, Ghaffari Laleh N, Gerstung M, Kather JN. Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. Nat Cancer. 2022;3:1026-38.
197. Courtiol P, Maussion C, Moarii M, et al. Deep learning-based classification of mesothelioma improves prediction of patient outcome. Nat Med. 2019;25:1519-25.
198. Galateau Salle F, Le Stang N, Nicholson AG, et al. New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH Reference Center. J Thorac Oncol. 2018;13:1189-203.
199. Marra A, Morganti S, Pareja F, et al. Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives. Ann Oncol. 2025;36:712-25.
200. Zhang C, de A F Fonseca L, Shi Z, et al. Systematic review of radiomic biomarkers for predicting immune checkpoint inhibitor treatment outcomes. Methods. 2021;188:61-72.
201. Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.
202. Li D, Cao Y, Petrella F, Zou Y. Malignant pleural mesothelioma treated with cytoreductive video-assisted thoracic surgery plus hyperthermic intrathoracic chemotherapy: a case report. J Thorac Dis. 2024;16:8133-41.
203. Choi HY, Chang JE. Targeted therapy for cancers: from ongoing clinical trials to FDA-approved drugs. Int J Mol Sci. 2023;24:13618.
204. Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019;20:1702-9.
205. Kutuk T, Atak E, La Rosa A, Kotecha R, Mehta MP, Chuong MD. Tumor treating fields: narrative review of a promising treatment modality for cancer. Chin Clin Oncol. 2023;12:64.
